Abstract

This study investigates the efficacy of a genetically modified Escherichia coli Nissle strain in mitigating liver injury in a mouse model of tyrosinemia type 1. Tyrosinemia type 1 is a metabolic disorder characterized by the accumulation of toxic metabolites derived from tyrosine metabolism, leading to severe liver damage and potentially fatal outcomes. In this research, we engineered a specialized E. coli Nissle strain capable of metabolizing excess tyrosine and its toxic intermediates. Mice afflicted with tyrosinemia type 1 were administered this modified bacterial strain orally, and their liver function and histopathology were assessed. Results demonstrate a significant reduction in liver injury markers and histological evidence of liver damage in mice treated with the modified E. coli Nissle strain compared to untreated controls. These findings suggest the potential therapeutic utility of engineered bacterial strains in managing tyrosinemia type 1 and related metabolic disorders.